Cargando…
EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression
Triple-negative breast cancers (TNBCs) are frequently poorly differentiated with high propensity for metastasis. Enhancer of zeste homolog 2 (EZH2) is the lysine methyltransferase of polycomb repressive complex 2 that mediates transcriptional repression in normal cells and in cancer through H3K27me3...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389258/ https://www.ncbi.nlm.nih.gov/pubmed/35992062 http://dx.doi.org/10.1016/j.isci.2022.104827 |
_version_ | 1784770404077797376 |
---|---|
author | Gonzalez, Maria E. Naimo, Giuseppina Daniela Anwar, Talha Paolì, Alessandro Tekula, Shilpa R. Kim, Suny Medhora, Natasha Leflein, Shoshana A. Itkin, Jacob Trievel, Raymond Kidwell, Kelley M. Chen, Yu-Chih Mauro, Loredana Yoon, Euisik Andò, Sebastiano Kleer, Celina G. |
author_facet | Gonzalez, Maria E. Naimo, Giuseppina Daniela Anwar, Talha Paolì, Alessandro Tekula, Shilpa R. Kim, Suny Medhora, Natasha Leflein, Shoshana A. Itkin, Jacob Trievel, Raymond Kidwell, Kelley M. Chen, Yu-Chih Mauro, Loredana Yoon, Euisik Andò, Sebastiano Kleer, Celina G. |
author_sort | Gonzalez, Maria E. |
collection | PubMed |
description | Triple-negative breast cancers (TNBCs) are frequently poorly differentiated with high propensity for metastasis. Enhancer of zeste homolog 2 (EZH2) is the lysine methyltransferase of polycomb repressive complex 2 that mediates transcriptional repression in normal cells and in cancer through H3K27me3. However, H3K27me3-independent non-canonical functions of EZH2 are incompletely understood. We reported that EZH2 phosphorylation at T367 by p38α induces TNBC metastasis in an H3K27me3-independent manner. Here, we show that cytosolic EZH2 methylates p38α at lysine 139 and 165 leading to enhanced p38α stability and that p38 methylation and activation require T367 phosphorylation of EZH2. Dual inhibition of EZH2 methyltransferase and p38 kinase activities downregulates pEZH2-T367, H3K27me3, and p-p38 pathways in vivo and reduces TNBC growth and metastasis. These data uncover a cooperation between EZH2 canonical and non-canonical mechanisms and suggest that inhibition of these pathways may be a potential therapeutic strategy. |
format | Online Article Text |
id | pubmed-9389258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93892582022-08-20 EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression Gonzalez, Maria E. Naimo, Giuseppina Daniela Anwar, Talha Paolì, Alessandro Tekula, Shilpa R. Kim, Suny Medhora, Natasha Leflein, Shoshana A. Itkin, Jacob Trievel, Raymond Kidwell, Kelley M. Chen, Yu-Chih Mauro, Loredana Yoon, Euisik Andò, Sebastiano Kleer, Celina G. iScience Article Triple-negative breast cancers (TNBCs) are frequently poorly differentiated with high propensity for metastasis. Enhancer of zeste homolog 2 (EZH2) is the lysine methyltransferase of polycomb repressive complex 2 that mediates transcriptional repression in normal cells and in cancer through H3K27me3. However, H3K27me3-independent non-canonical functions of EZH2 are incompletely understood. We reported that EZH2 phosphorylation at T367 by p38α induces TNBC metastasis in an H3K27me3-independent manner. Here, we show that cytosolic EZH2 methylates p38α at lysine 139 and 165 leading to enhanced p38α stability and that p38 methylation and activation require T367 phosphorylation of EZH2. Dual inhibition of EZH2 methyltransferase and p38 kinase activities downregulates pEZH2-T367, H3K27me3, and p-p38 pathways in vivo and reduces TNBC growth and metastasis. These data uncover a cooperation between EZH2 canonical and non-canonical mechanisms and suggest that inhibition of these pathways may be a potential therapeutic strategy. Elsevier 2022-08-02 /pmc/articles/PMC9389258/ /pubmed/35992062 http://dx.doi.org/10.1016/j.isci.2022.104827 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Gonzalez, Maria E. Naimo, Giuseppina Daniela Anwar, Talha Paolì, Alessandro Tekula, Shilpa R. Kim, Suny Medhora, Natasha Leflein, Shoshana A. Itkin, Jacob Trievel, Raymond Kidwell, Kelley M. Chen, Yu-Chih Mauro, Loredana Yoon, Euisik Andò, Sebastiano Kleer, Celina G. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title | EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title_full | EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title_fullStr | EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title_full_unstemmed | EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title_short | EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
title_sort | ezh2 t367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389258/ https://www.ncbi.nlm.nih.gov/pubmed/35992062 http://dx.doi.org/10.1016/j.isci.2022.104827 |
work_keys_str_mv | AT gonzalezmariae ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT naimogiuseppinadaniela ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT anwartalha ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT paolialessandro ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT tekulashilpar ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT kimsuny ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT medhoranatasha ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT lefleinshoshanaa ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT itkinjacob ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT trievelraymond ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT kidwellkelleym ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT chenyuchih ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT mauroloredana ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT yooneuisik ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT andosebastiano ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression AT kleercelinag ezh2t367phosphorylationactivatesp38signalingthroughlysinemethylationtopromotebreastcancerprogression |